ubrogepant 50 MG Oral Tablet [Ubrelvy]
Managing this medication for someone you care for? Eleplan keeps diagnoses, medications and appointments in one plan.
Start free with EleplanClinical drug
ubrogepant 50 MG Oral Tablet [Ubrelvy]
50 MG · Oral Tablet · oral
A form of ubrogepant →
ubrogepant 50 MG Oral Tablet [Ubrelvy] — Calcitonin gene-related peptide (CGRP) antagonists. Strength, form, class, interactions & more.
![ubrogepant 50 MG Oral Tablet [Ubrelvy]](https://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fd9f9458-fd96-4688-be3f-f77b3d1af6ab&name=ubrelvy-01.jpg)
Active ingredient
Classification
Calcitonin gene-related peptide (CGRP) antagonistsCalcitonin Gene-related Peptide Receptor Antagonist
Drug interactions
Ubrogepant has several drug interactions primarily involving CYP3A4 inhibitors and inducers, as well as BCRP and P-gp inhibitors.
- majorstrong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John’s Wort) — loss of ubrogepant efficacy is expected
- majorstrong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin) — significant increase in exposure of ubrogepant
- moderatemoderate CYP3A4 inhibitors (e.g., cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, grapefruit juice) — increase in ubrogepant exposure
- moderateBCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) — may increase the exposure of ubrogepant
Source: RxNorm + openFDA + RxClass + FAERS · 2026
Look up another medication